Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Prostate Adenocarcinoma: early-phase trial registry
10 of 19 indexed Metastatic Prostate Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 10 currently recruiting · #902 of 28,707 conditions by registered trial count
Metastatic Prostate Adenocarcinoma: 19 US clinical trials tracked, 10 recruiting.
Metastatic Prostate Adenocarcinoma is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 2 of these trials.
Enrollment posture brief
Registry condition metastatic-prostate-adenocarcinoma
OPEN 10 | RECR 53% | LATE 2 | EARLY 17 | RANK #902 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Colorectal Cancer Metastatic (53% recruiting · 19 trials)
Metastatic Prostate Adenocarcinoma lists 10 open slots (53% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Prostate Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Prostate Adenocarcinoma is recruiting above its size-band peers.
10 of 19 indexed trials (52.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Prostate Adenocarcinoma trials is spread across many organizations.
Alliance for Clinical Trials in Oncology accounts for 2 of 19 trials (10.5%). 16 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Prostate Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 47 among the 19 trials that report a genuine target (sentinel values excluded). 16 of those (84.2%) plan for fewer than 100 participants.
-
Metastatic Prostate Adenocarcinoma research is mostly interventional.
19 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
NCT06931340
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
M.D. Anderson Cancer Center
NCT05054296
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
NCT04734730
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
University of Washington
NCT06039371
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
NCT06236139
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04704505
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
NCT06616155
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
University of Utah
NCT05168618
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Vadim S Koshkin
NCT05113537
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
NCT06145633
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
National Cancer Institute (NCI)
NCT03317392
A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer
Mayo Clinic
NCT04190446
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Alliance for Clinical Trials in Oncology
NCT04455750
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Rahul Aggarwal
NCT04471974
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT03902951
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
NCT05689021
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Rashmi Verma, MD
NCT05479578
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
OHSU Knight Cancer Institute
NCT02099864
Evaluation of PSMA Antagonist Produced by Two Different Methods
Weill Medical College of Cornell University
NCT04685811
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 11 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Prostate Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Prostate Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Prostate Adenocarcinoma page
19 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Metastatic Prostate Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alliance for Clinical Trials in Oncology sponsors the most Metastatic Prostate Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Alliance for Clinical Trials in Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Prostate Adenocarcinoma condition card totals 19 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.